Garenoxacin in Skin and Skin Structure Infections Sustained due to Road Traffic Accident
Published: June 1, 2014 | DOI: https://doi.org/10.7860/JCDR/2014/.4458
Mahesh Mohanlal Pukar, Anoop Laxminarayan Hajare, K. Krishnaprasad, Am it Indra Bhargava
1. Professor, General Surgery, Department of Surgery, SBKSMIRC, Vadodara, India.
2. Medical Advisor, Department of Medical Services, Glenmark Pharmaceuticals, Mumbai, India.
3. Senior Medical Advisor, Department of Medical Services, Glenmark Pharmaceuticals, Mumbai, India.
4. Head & VP, Department of Medical Services, Glenmark Pharmaceuticals Mumbai, India.
Correspondence Address :
Dr. Anoop Laxminarayan Hajare,
H.No. 9-880, Shahabazar, Gulbarga – 585101, Karnataka, India.
Phone: 09619292787, E-mail: anoophajare@gmail.com
Abstract
Skin and soft tissue infections represent a continuum of symptoms that range from uncomplicated cellulitis to the potentially lethal entity necrotizing fasciitis that is often considered to be microbial invasions of the epidermis, dermis and subcutaneous tissues. Garenoxacin, a newer oral des-fluoroquinolone having potent antimicrobial activity against wide variety of common pathogens involved in skin and skin structure infections (SSTIs), including the resistant strains offer the advantage of broad spectrum of coverage including gram positive, gram negative and anaerobic organisms. This case study indicates the utility of garenoxacin in treating skin and soft tissue infections caused by road traffic accidents.
Keywords
Broad-spectrum antibiotic, Newer fluoroquinolone, Resistance, SSTI, Wounds